REVA Medical 8K Appendix 4C Quarter Ended 30 September 2011 | RVALL 28 Oct 11

Exhibit 99.1

Appendix 4C
Quarter Ended 30 September 2011

San Diego, California and Sydney, Australia (Friday 28 October 2011, AEDT)— REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) is pleased to provide its Appendix 4C Quarterly Report for the quarter ended 30 September 2011. The Appendix 4C is attached; it is unaudited.

As of 30 September 2011, the Company’s cash balance was US$64,971,000 and its interest-bearing investments were US$4,230,000 for a total of US$69,201,000. The current quarter end total reflects a decrease of US$3,779,000 from the 30 June 2011 quarter end balance of US$72,980,000, primarily as a result of expenditures related to normal operating activities and capital equipment purchases of US$214,000.

The Company will file its Form 10-Q Quarterly Report (the “Quarterly Report”) with the Securities and Exchange Commission on or before 15 August 2011. The Quarterly Report provides financial statements, along with Management’s Discussion and Analysis of Financial Condition and Results of Operations, for the period ended 30 September 2011. Additionally, the Company’s Chairman and Chief Executive Officer provided an update of activities in a Letter to Shareholders on 25 October 2011; a copy of the letter is available on the Company’s website.

About REVA

REVA is a development stage medical device company incorporated in Delaware, USA, that is focused on the development and eventual commercialisation of its proprietary, bioresorbable stent products. REVA’s lead product, theReZolve™stent, combines REVA’s proprietary stent design with a proprietary polymer that is metabolised and cleared from the body. TheReZolvestent is designed to offer full x-ray visibility, clinically relevant sizing and a controlled and safe resorption rate. In addition, by early encapsulation of the stent in the artery tissue coupled with the loss of stent structure over time, theReZolvestent may reduce the incidence of late forming blood clots, or thrombosis, a rare but serious problem associated with drug-eluting metal stents currently on the market. REVA is in the process of finalising the design and testing of itsReZolve stent and will require clinical results and regulatory approval before it can begin selling theReZolve™stent.

HEAD OFFICE: 5751 Copley Drive, Suite B, San Diego, CA 92111• +1 (858) 966-3000• +1 (858) 966-3099 (FAX)•
www.revamedical.com
AUSTRALIAN OFFICE: Level 6, 175 Macquarie Street, Sydney, NSW 2000• +61 2 9231 3322• +61 9229 2727 (FAX)•
ARBN 146 505 777
REVA Medical, Inc., is a foreign company incorporated in Delaware, USA, whose stockholders have limited liability.



REVA Medical, Inc. — ASX Announcement		Page 2

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management’s beliefs, assumptions and expectations and on information currently available to management. All statements that are not historical, including those statements that address future operating performance and events or developments that we expect or anticipate will occur in the future, are forward-looking statements. You should not place undue reliance on these forward-looking statements. Although management believes these forward-looking statements are reasonable as and when made, forward-looking statements are subject to a number of risks and uncertainties that may cause our actual results to vary materially from those expressed in the forward-looking statements, including our ability to obtain the regulatory approvals required to market our ReZolve stent, our ability to timely and successfully complete our clinical trials, our ability to protect our intellectual property position, our ability to commercialize our products if and when approved, our ability to develop and commercialize new products, and our estimates regarding our capital requirements and financial performance, including profitability. Other risks and uncertainties that may cause our actual results to vary materially from any forward-looking statements are described in the “Risk Factors” section in our Annual Report onForm 10-K filed with the United States Securities and Exchange Commission (the “SEC”) on 30 March 2011, as updated in our Quarterly Reports onForm 10-Q filed with the SEC for the periods ended 31 March 2011 and 30 June 2011. We may update our risk factors from time to time in our periodic reports or other current reports filed with the SEC. Any forward-looking statements in this announcement speak only as of the date when made. REVA does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.


United States Investor and Media Enquiries: Cheryl Liberatore Director, Investor Relations and Marketing REVA Medical, Inc. +1 858-966-3045		Australia Investor Enquiries: David Allen or Alan Taylor Inteq Limited +61 2 9231 3322 Media Enquiries: Kyahn Williamson & Rebecca Wilson Buchan Consulting + 61 3 9866 4722

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

Rule 4.7B

Appendix 4C

Quarterly report
for entities admitted
on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001, 24/10/2005.


Name of entity REVA Medical, Inc.


ABN		Quarter ended (“current quarter”)
ARBN 146 505 777		30 September 2011

Consolidated statement of cash flows


	Current Quarter			Year to date
	(Q3)			(9 months)
	$’000 USD			$’000 USD
Cash flows related to operating activities
1.1 Receipts from customers		0			0

1.2 Payments for
(a) staff costs		(1,680	)		(4,974	)
(b) advertising and marketing		0			0
(c) research and development		(1,289	)		(4,730	)
(d) leased assets		0			0
(e) other working capital		(646	)		(2,288	)
1.3 Dividends received		0			0
1.4 Interest and other items of a similar nature received		40			246
1.5 Interest and other costs of finance paid		0			0
1.6 Income taxes paid		0			0
1.7 Other (provide details if material)		0			282

Net operating cash flows		(3,575	)		(11,464	)

+ See chapter 19 for defined terms.



24/10/2005		Appendix 4C Page 1

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments


	Current Quarter			Year to date
	(Q3)			(9 months)
	$’000 USD			$’000 USD
1.8 Net operating cash flows (carried forward)		(3,575	)		(11,464	)


Cash flows related to investing activities
1.9 Payment for acquisition of:
(a) businesses (item 5)		0			0
(b) equity investments		0			0
(c) intellectual property		0			0
(d) physical non-current assets		(214	)		(673	)
(e) other non-current assets		0			0
1.10 Proceeds from disposal of:
(a) businesses (item 5)		0			0
(b) equity investments		0			0
(c) intellectual property		0			0
(d) physical non-current assets		0			7
(e) other non-current assets		0			0
1.11 Loans to other entities		0			0
1.12 Loans repaid by other entities		0			0
1.13 Other (purchases of Certificates of Deposit)		(4,230	)		(4,230	)

Net investing cash flows		(4,444	)		(4,896	)

1.14 Total operating and investing cash flows		(8,019	)		(16,360	)


Cash flows related to financing activities
1.15 Proceeds from issues of shares, options, etc.		10			16
1.16 Proceeds from sale of forfeited shares		0			0
1.17 Proceeds from borrowings		0			0
1.18 Repayment of borrowings		0			0
1.19 Dividends paid		0			0
1.20 Other (2010 capital raising costs)		0			(432	)

Net financing cash flows		10			(416	)


Net increase (decrease) in cash held		(8,009	)		(16,776	)

1.21 Cash at beginning of quarter/year to date		72,980			81,747
1.22 Exchange rate adjustments to item 1.20		0			0

1.23Cash at end of quarter		64,971			64,971

+ See chapter 19 for defined terms.



Appendix 4C Page 2		24/10/2005

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities


	Current Quarter
	(Q3)
	$’000 USD
1.24 Aggregate amount of payments to the parties included in item 1.2		135
1.25 Aggregate amount of loans to the parties included in item 1.11		0

1.26 Explanation necessary for an understanding of the transactions
Australian Director fees (2 non-executive directors)		20
U.S Director fees (3 non-executive directors)		27
U.S. Director salary (1 executive director)		88

Non-cash financing and investing activities

2.1		Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

		N/A

2.2		Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

		N/A

Financing facilities available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).


	Amount available		Amount used
	$’000 USD		$’000 USD
3.1 Loan facilities		0		0
3.2 Credit standby arrangements		0		0

+ See chapter 19 for defined terms.



24/10/2005		Appendix 4C Page 3

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.


	Current Quarter		Previous Quarter
	(Q3)		(Q2)
	$’000 USD		$’000 USD
4.1 Cash on hand and at bank		46		215
4.2 Deposits at call		64,925		72,765
4.3 Bank overdraft		0		0
4.4 Other (provide details)		0		0

Total: cash at end of quarter(item 1.23)		64,971		72,980

Acquisitions and disposals of business entities


	Acquisitions		Disposals
	(Item 1.9(a))		(Item 1.10(a))
5.1 Name of entity		N/A		N/A
5.2 Place of incorporation or registration
5.3 Consideration for acquisition or disposal
5.4 Total net assets
5.5 Nature of business

Compliance statement


1		This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.

2		This statement does give a true and fair view of the matters disclosed.


Sign here:		/s/ Katrina L. Thompson (Chief Financial Officer/Company Secretary)		Date: 28 October 2011

Print name: Katrina L. Thompson

+ See chapter 19 for defined terms.



Appendix 4C Page 4		24/10/2005

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

Notes

The quarterly report provides a basis for informing the market how the entity’s activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.

The definitions in, and provisions of,AASB 1026: Statement of Cash Flowsapply to this report except for the paragraphs of the Standard set out below.

	•		6.2 — reconciliation of cash flows arising from operating activities to operating profit or loss

	•		9.2 — itemised disclosure relating to acquisitions

	•		9.4 — itemised disclosure relating to disposals

	•		12.1(a) — policy for classification of cash items

	•		12.3 — disclosure of restrictions on use of cash

	•		13.1 — comparative information

Accounting Standards.ASX will accept, for example, the use of International Accounting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

+ See chapter 19 for defined terms.



24/10/2005		Appendix 4C Page 5

REVA Medical (RVALL) 8-KAppendix 4C Quarter Ended 30 September 2011